AxoGen (NASDAQ:AXGN) Director Sells $70,162.20 in Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 1,647 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $42.60, for a total transaction of $70,162.20. Following the completion of the transaction, the director owned 93,826 shares of the company’s stock, valued at approximately $3,996,987.60. This trade represents a 1.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

AxoGen Trading Up 0.3%

NASDAQ AXGN traded up $0.14 during trading hours on Tuesday, reaching $40.93. The company’s stock had a trading volume of 643,710 shares, compared to its average volume of 1,036,576. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $45.83. The firm has a fifty day simple moving average of $34.60 and a 200-day simple moving average of $31.50. The stock has a market cap of $2.18 billion, a P/E ratio of -63.95 and a beta of 1.17.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The firm had revenue of $61.46 million for the quarter, compared to the consensus estimate of $57.85 million. Equities analysts forecast that AxoGen, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Raymond James Financial restated an “outperform” rating and set a $48.00 price target on shares of AxoGen in a report on Wednesday, April 29th. Canaccord Genuity Group raised their price target on shares of AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. HC Wainwright raised their price target on shares of AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Citigroup restated an “outperform” rating on shares of AxoGen in a report on Wednesday, April 29th. Finally, Citizens Jmp raised their price target on shares of AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a report on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $46.50.

Institutional Trading of AxoGen

Several large investors have recently modified their holdings of AXGN. MCF Advisors LLC acquired a new stake in shares of AxoGen during the 4th quarter worth approximately $30,000. Aquatic Capital Management LLC grew its position in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares during the period. Arax Advisory Partners grew its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 819 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of AxoGen during the 4th quarter worth approximately $36,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of AxoGen during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.